Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
Jo Lynne Rokita, Komal S. Rathi, Maria Cardenas, et al.
Cell Reports (2019) Vol. 29, Iss. 6, pp. 1675-1689.e9
Open Access | Times Cited: 140

Showing 1-25 of 140 citing articles:

Advancing therapy for osteosarcoma
Jonathan Gill, Richard Görlick
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 10, pp. 609-624
Closed Access | Times Cited: 554
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations
Anita Villani, Scott Davidson, Nisha Kanwar, et al.
Nature Cancer (2022) Vol. 4, Iss. 2, pp. 203-221
Open Access | Times Cited: 76
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
Meenakshi Anurag, Eric J. Jaehnig, Karsten Krug, et al.
Cancer Discovery (2022) Vol. 12, Iss. 11, pp. 2586-2605
Open Access | Times Cited: 73
RETRACTED ARTICLE: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich, Quinlen F. Marshall, John M. Warrington, et al.
Nature (2021) Vol. 599, Iss. 7885, pp. 477-484
Open Access | Times Cited: 94
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
David A. Wheeler, Naoko Takebe, Toshinori Hinoue, et al.
Cancer Cell (2020) Vol. 39, Iss. 1, pp. 38-53.e7
Open Access | Times Cited: 89
The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
Nathan M. Kendsersky, Jarrett M. Lindsay, E. Anders Kolb, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 10, pp. 2938-2946
Open Access | Times Cited: 89
Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma
Balakrishna Koneru, Gonzalo López, Ahsan Farooqi, et al.
Cancer Research (2020) Vol. 80, Iss. 12, pp. 2663-2675
Open Access | Times Cited: 81
Canine and murine models of osteosarcoma
Jessica A. Beck, Ling Ren, Shan Huang, et al.
Veterinary Pathology (2022) Vol. 59, Iss. 3, pp. 399-414
Open Access | Times Cited: 42
Epigenetic state determines inflammatory sensing in neuroblastoma
Adam J. Wolpaw, Liron D. Grossmann, Jessica L. Dessau, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 6
Open Access | Times Cited: 41
Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies
Ali Zarrabi, David Perrin, Mahboubeh Kavoosi, et al.
Cancers (2023) Vol. 15, Iss. 21, pp. 5269-5269
Open Access | Times Cited: 37
Targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich, Quinlen F. Marshall, John M. Warrington, et al.
Nature (2023) Vol. 623, Iss. 7988, pp. 820-827
Open Access | Times Cited: 30
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Nicolás Anselmino, Estefanía Labanca, Peter D.A. Shepherd, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2272-2285
Open Access | Times Cited: 11
Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma
Jichuan Wang, Alexander Ferrena, Ranxin Zhang, et al.
Oncogene (2024) Vol. 43, Iss. 13, pp. 962-975
Open Access | Times Cited: 8
The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia
Ben Watts, Christopher M. Smith, Kathryn L. Evans, et al.
HemaSphere (2025) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia
Cédric S. Tremblay, Jesslyn Saw, Feng Yan, et al.
Leukemia (2025)
Open Access | Times Cited: 1
Rapid Processing and Drug Evaluation in Glioblastoma Patient-Derived Organoid Models with 4D Bioprinted Arrays
Michelle Chadwick, Chen Yang, Liqiong Liu, et al.
iScience (2020) Vol. 23, Iss. 8, pp. 101365-101365
Open Access | Times Cited: 63
Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource
Kyle Smith, Ke Xu, Kimberly Mercer, et al.
Acta Neuropathologica (2020) Vol. 140, Iss. 2, pp. 209-225
Open Access | Times Cited: 55
ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156
Balakrishna Koneru, Ahsan Farooqi, Thinh H. Nguyen, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 607
Open Access | Times Cited: 46
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
Adam J. Wolpaw, Richard Bayliss, Gabriele Büchel, et al.
Cancer Research (2021) Vol. 81, Iss. 7, pp. 1627-1632
Open Access | Times Cited: 45
Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy
Chiara Brignole, Veronica Bensa, Nuno A. Fonseca, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 42
miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma
Anup Singh Pathania, Philip Prathipati, Omalla A. Olwenyi, et al.
Molecular Therapy — Oncolytics (2022) Vol. 25, pp. 308-329
Open Access | Times Cited: 28
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Mawar Karsa, Lin Xiao, Emma Ronca, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 4, pp. 507-519
Open Access | Times Cited: 8
Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Yifei Wang, Xiangjun Tian, Wendong Zhang, et al.
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 6, pp. 903-913
Open Access | Times Cited: 24
Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Courtney R. Schott, Amanda Koehne, Leanne C. Sayles, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 849-864
Open Access | Times Cited: 14
Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Brian Mooney, Gian Luca Negri, Taras Shyp, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 5, pp. 1022-1037
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top